Understanding Anti-Nuclear Antibodies and Their Role in Autoimmune Disease Screening
Samwel Mikaye, Chief Executive Officer at Samik Medical Center, shared in the Laboratory Professionals International group on LinkedIn:
”Anti-Nuclear Antibody (ANA)
What Are They?
Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that mistakenly attack the nucleus of the body’s own cells. The nucleus contains DNA, RNA, and associated proteins, so ANA may target these nuclear components, including nucleotides.
Why Are ANA Tested?
The ANA test is mainly used to screen for autoimmune diseases, especially:
• Systemic Lupus Erythematosus (SLE) — most commonly associated
• Sjögren’s Syndrome
• Scleroderma (Systemic Sclerosis)
• Mixed Connective Tissue Disease
• Autoimmune Thyroid Disorders (sometimes)
• Rheumatoid Arthritis (occasionally)
How Is the Test Reported?
• Results are given as titers, such as 1:40, 1:160, or 1:320.
• A higher titer suggests stronger autoimmune activity.
• The pattern seen in the lab (e.g., homogeneous, speckled, nucleolar, or centromere) may help indicate which autoimmune condition is more likely — but pattern alone is not diagnostic.
Important Interpretation Notes
• A positive ANA does not always mean disease.
• Many healthy individuals, especially elderly or those with infections, may have low-level ANA positivity.
• A negative ANA makes lupus very unlikely, but does not completely rule out all autoimmune disorders.
• Additional specific antibody tests (like anti-dsDNA, anti-Smith, anti-Ro/La) are often required to confirm diagnosis.
Key Takeaways
- ANA are antibodies that react against the body’s own cell nuclei
- Used mainly as a screening tool for autoimmune diseases like lupus
- Positive ANA alone is not enough for diagnosis — symptoms and further tests are essential
- Negative ANA reduces likelihood of lupus significantly.”
Stay updated with Hemostasis Today.
-
Sep 7, 2026, 08:17Nasim Hosseini: Women’s Blood Donation and the Social Determinants of Health
-
Sep 7, 2026, 08:12David McIntosh: The Global Plasma Supply Debate
-
Sep 7, 2026, 08:03Julio Avella: Advancing IDA Care Through Scientific Education and Collaboration
-
Sep 6, 2026, 18:17Aryabhatta Sadhu: Irradiation of Blood Components – From Clinical Indication to Laboratory Release
-
Sep 6, 2026, 18:15Ashenafi Tazebew Amare: A Year of Progress, Transformation and Renewed Commitment
-
Sep 6, 2026, 18:13Emilio Osorio: Can Anticoagulation Be Safely Discontinued After Surgical Left Atrial Appendage Occlusion?
-
Sep 6, 2026, 18:11Razan Alolyani: Our Research on Anticoagulation After Acute Ischemic Stroke Receives 2nd Place
-
Sep 6, 2026, 18:10Chayakrit Krittanawong: Have You Heard of Blood Clots in the Legs?
-
Sep 6, 2026, 18:08Trilok Chand: Microplastics Found in Human Testes and Blood Clots